1,3-di-O-caffeoylquinic acid | 212891-05-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1,3-di-O-caffeoylquinic acid
• 英文别名: cynarine；Cynarin；(1R,3R,4S,5R)-1,3-bis{[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-4,5-dihydroxycyclohexanecarboxylic acid；1-trans,3-trans-dicaffeoylquinic acid；1,5-di-O-caffeoylquinic acid；1,3-O-dicaffeoylquinic acid；(1R,3R,4S,5R)-1,3-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-4,5-dihydroxycyclohexane-1-carboxylic acid
• CAS: 212891-05-9
• 化学式: C₂₅H₂₄O₁₂
• 分子量: 516.458
• InChiKey: YDDUMTOHNYZQPO-RVXRWRFUSA-N

物化性质

• 沸点：
  819.9±65.0 °C(Predicted)
• 密度：
  1?+-.0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  37
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  211
• 氢给体数：
  7
• 氢受体数：
  12

反应信息

• 作为反应物：
  描述：

  1,3-di-O-caffeoylquinic acid 在 盐酸 作用下， 反应 2.0h， 生成 neochlorogenic acid
  参考文献：
  名称：

  Discriminating between the Six Isomers of Dicaffeoylquinic Acid by LC-MSⁿ

  摘要：

  The fragmentation behavior of all six dicaffeoylquinic acids (diCQA) has been investigated using LC-MS4. It is possible to discriminate between each of the isomers including those for which commercial standards are not available. For diCQA, the ease of removal of the caffeoyl residue during fragmentation is 1 approximate to 5 > 3 > 4. The distinctive fragmentation observed for the little-studied 1,4- dicaffeoylquinic acid involves elimination of the C1 caffeoyl residue, repeated dehydrations leading to the aromatization of the quinic acid moiety, and its decarboxylation. It is suggested that this process is initiated by the C1 carboxyl protonating the C5 hydroxyl in the inverted chair conformer, followed by its protonating the C1 caffeoyl residue in the favored chair conformation. The fragmentation of 1-caffeoylquinic acid is indistinguishable from that of the commercially available 5-caffeoylquinic acid, but these two isomers can be distinguished easily by their facile chromatographic resolution on reversed phase packings. The hierarchical key previously developed for characterizing chlorogenic acids has been extended to accommodate 1-caffeoylquinic acid and the 1-acyl dicaffeoylquinic acids.

  DOI：

  10.1021/jf050046h
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 生成 1,3-di-O-caffeoylquinic acid
  参考文献：
  名称：

  Panizzi et al., Gazzetta Chimica Italiana, 1954, vol. 84, p. 806,811

  摘要：

  DOI：

文献信息

• Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers
  申请人：Bezwada Rao S.

  公开号：US20120035259A1

  公开（公告）日：2012-02-09

  The present invention provides NO and, optionally, drug releasing macromers and oligomers wherein the drug molecule and NO releasing moiety are linked an absorbable macromer or oligomeric chain susceptible to hydrolytic degradation and wherein the macromer or oligomer comprises of repeat units derived from safe and biocompatible molecules such as glycolic acid, lactic acid, caprolactone and p-dioxanone. Furthermore, the present invention relates to controlled release of nitric oxide (NO) and/or drug molecule from a NO and drug releasing macromer or oligomer. Moreover, the present invention also relates to medical devices, medical device coatings and therapeutic formulations comprising of nitric oxide and drug releasing macromers and oligomers of the present invention.

  本发明提供了一氧化氮(NO)和可选的药物释放的大分子和寡聚物，其中药物分子和一氧化氮释放部分通过可吸收的大分子或可水解降解的寡聚物链连接，并且大分子或寡聚物由来自诸如乙醇酸、乳酸、己内酰胺和对二恶烷等安全且生物相容的分子的重复单元组成。此外，本发明还涉及从一氧化氮和/或药物分子释放的大分子或寡聚物控制释放一氧化氮(NO)。此外，本发明还涉及包含本发明的一氧化氮和药物释放大分子和寡聚物的医疗器械、医疗器械涂层和治疗方法。
• ABSORBABLE BRANCHED POLYESTERS AND POLYURETHANES
  申请人：Bezwada Biomedical, LLC

  公开号：US20140142199A1

  公开（公告）日：2014-05-22

  The present invention relates to the discovery of a new class of hydrolysable isocyanates, hydrolysable branched polyols and branched absorbable polyesters and polyurethanes prepared therefrom. The resultant absorbable polymers are useful for drug delivery, stents, highly porous foam, reticulated foam, tissue engineering, tissue adhesives, adhesion prevention, bone wax formulations, medical device coatings, surface modifying agents and other implantable medical devices. In addition, these absorbable polymers can have a controlled hydrolytic degradation profile.

  本发明涉及一种新型可水解异氰酸酯、可水解支链多元醇及其制备的支链可吸收聚酯和聚氨酯的发现。由此得到的可吸收聚合物可用于药物输送、支架、高孔隙率泡沫、网状泡沫、组织工程、组织粘合剂、防止粘连、骨蜡制剂、医疗设备涂层、表面改性剂以及其他可植入医疗设备。此外，这些可吸收聚合物可以具有受控的水解降解特性。
• Preferential alkali metal adduct formation by <i>cis</i> geometrical isomers of dicaffeoylquinic acids allows for efficient discrimination from their <i>trans</i> isomers during ultra-high-performance liquid chromatography/quadrupole time-of-flight mass spectrometry
  作者：Mpho M. Makola、Paul. A Steenkamp、Ian A. Dubery、Mwadham M. Kabanda、Ntakadzeni E. Madala

  DOI：10.1002/rcm.7526

  日期：2016.4.30

  RATIONALE Caffeoylquinic acid (CQA) derivatives are a group of structurally diverse phytochemicals that have attracted attention due to their many health benefits. The structural diversity of these molecules is due in part to the presence of regio- and geometrical isomerism. This structural diversity hampers the accurate annotation of these molecules in plant extracts. Mass spectrometry (MS) is successfully

  理性咖啡酰奎尼酸（CQA）衍生物是一组结构多样的植物化学物质，由于它们具有许多健康益处，因此引起了人们的关注。这些分子的结构多样性部分归因于区域和几何异构现象的存在。这种结构多样性妨碍了植物提取物中这些分子的准确注释。质谱（MS）已成功用于区分CQA衍生物的不同区域异构体；然而，事实证明，对这些分子的几何异构体进行准确区分是一项艰巨的任务。方法采用超高效液相色谱/四极杆飞行时间质谱（UHPLC / QTOFMS）方法在负离子化模式下对diCQA的甲醇溶液进行紫外线辐射分析。通过改变毛细管电压和锥孔电压来优化源内碰撞诱导解离（ISCID）方法，以实现MS分析过程中diCQA的UV生成的几何异构体之间的差异碎片化模式。结果毛细管电压的变化并没有引起四种几何异构体的断裂图谱的显着差异，而视锥电压的变化却导致了断裂图谱的显着差异。结果还首次显示，与diCQAs的反式对应物相比，diCQAs的顺式几
• BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF
  申请人：SENOMYX, INC.

  公开号：US20160376263A1

  公开（公告）日：2016-12-29

  The present invention includes compounds and compositions known to modify the perception of bitter taste, and combinations of said compositions and compounds with additional compositions, compounds, and products. Exemplary compositions comprise one or more of the following: cooling agents; inactive drug ingredients; active pharmaceutical ingredients; food additives or foodstuffs; flavorants, or flavor enhancers; food or beverage products; bitter compounds; sweeteners; bitterants; sour flavorants; salty flavorants; umami flavorants; plant or animal products; compounds known to be used in pet care products; compounds known to be used in personal care products; compounds known to be used in home products; pharmaceutical preparations; topical preparations; cannabis-derived or cannabis-related products; compounds known to be used in oral care products; beverages; scents, perfumes, or odorants; compounds known to be used in consumer products; silicone compounds; abrasives; surfactants; warming agents; smoking articles; fats, oils, or emulsions; and/or probiotic bacteria or supplements.

  本发明涵盖已知用于改变苦味感知的化合物和组合物，以及所述组合物和化合物与额外的组合物、化合物和产品的组合。示例组合物包括以下一种或多种：冷却剂；无活性药物成分；活性药用成分；食品添加剂或食品；调味剂或调味增强剂；食品或饮料产品；苦味化合物；甜味剂；苦味剂；酸味调味剂；咸味调味剂；鲜味调味剂；植物或动物产品；已知用于宠物护理产品中的化合物；已知用于个人护理产品中的化合物；已知用于家用产品中的化合物；制药制剂；局部制剂；大麻衍生或与大麻相关的产品；已知用于口腔护理产品中的化合物；饮料；香味、香水或除臭剂；已知用于消费品中的化合物；硅化合物；磨料；表面活性剂；发热剂；吸烟物品；脂肪、油脂或乳化剂；和/或益生菌或补充剂。
• Functionalized drugs and polymers derived therefrom
  申请人：Bezwada S. Rao

  公开号：US20060172983A1

  公开（公告）日：2006-08-03

  Compounds selected from: where DRUG-OH, DRUG-COOH and DRUG-NH 2 are biologically active compounds; each X is independently selected from —CH 2 COO— (glycolic acid moiety), —CH(CH 3 )COO— (lactic acid moiety), —CH 2 CH 2 OCH 2 COO— (dioxanone moiety), —CH 2 CH 2 CH 2 CH 2 CH 2 COO— (caprolactone moiety), —(CH 2 ) y COO—, where y is 2-4 or 6-24 and —(CH 2 CH 2 O) z CH 2 COO—, where z is 2-24; each Y is independently selected from —COCH 2 O— (glycolic ester moiety), —COCH(CH 3 )O— (lactic ester moiety), —COCH 2 OCH 2 CH 2 O— (dioxanone ester moiety), —COCH 2 CH 2 CH 2 CH 2 CH 2 O— (caprolactone ester moiety), —CO(CH 2 ) m O—, where m is 2-4 or 6-24 and —COCH 2 O(CH 2 CH 2 O) n — where n is between 2-24; R′ is hydrogen, benzyl or an alkyl group, the alkyl group being either straight-chained or branched; and p is 1-6. Multi-functional compounds and drug dimers, oligomers and polymers are also disclosed.

  从中选择的化合物：其中DRUG-OH，DRUG-COOH和DRUG-NH2是生物活性化合物；每个X独立地从—CH2COO—（乙二酸基团），—CH(CH3)COO—（乳酸基团），—CH2CH2OCH2COO—（二氧杂环己酮基团），—CH2CH2CH2CH2CH2COO—（己内酯基团），—(CH2)yCOO—中选择，其中y为2-4或6-24和—(CH2CH2O)zCH2COO—，其中z为2-24；每个Y独立地从—COCH2O—（乙二酸酯基团），—COCH(CH3)O—（乳酸酯基团），—COCH2OCH2CH2O—（二氧杂环己酮酯基团），—COCH2CH2CH2CH2CH2O—（己内酯酯基团），—CO(CH2)mO—，其中m为2-4或6-24和—COCH2O(CH2CH2O)n—，其中n为2-24；R′为氢，苄基或烷基，烷基可以是直链或支链；p为1-6。还披露了多功能化合物和药物二聚体、寡聚体和聚合物。